Stocksigma LogoStocksigma Logo

Aurobindo Pharma Subsidiary Apitoria Unit-II Receives US FDA EIR with VAI Classification

Aurobindo Pharma鈥檚 wholly owned subsidiary, Apitoria Pharma Private Limited, has received an Establishment Inspection Report (EIR) from the US FDA for its

Aurobindo Pharma Subsidiary Apitoria Unit-II Receives US FDA EIR with VAI Classification

Aurobindo Pharma Ltd 路 Others (Uncategorized) 路 11 Nov 2026, 5:04 pm

Aurobindo Pharma Subsidiary Apitoria Unit-II Receives US FDA EIR with VAI Classification Aurobindo Pharma鈥檚 wholly owned subsidiary, Apitoria Pharma Private Limited, has received an Establishment Inspection Report (EIR) from the US FDA for its Unit-II API manufacturing facility at Gaddapotharam, Telangana. The regulatory agency classified the facility as "Voluntary Action Indicated" (VAI) following its inspection conducted between 7th Sep'26 and 15th Sep'26. The US FDA has officially concluded that the inspection is closed under 21 CFR 20.64(d)(3), clearing regulatory overhang for the manufacturing unit.

Original exchange filing (PDF)

More announcements from Aurobindo Pharma Ltd

All Aurobindo Pharma Ltd announcements